김명철 교수 연구실
preprint|
green
·인용수 0
·2025
Dual Targeting of IKKβ and NR4A1 for AML Therapy
Chandra K. Maharjan, Yi Liu, Yufeng Xiao, Bristy Rani Podder, Terri Montgomery, Lei Wang, Myung‐Chul Kim, Zeng Jin, Seyedehalaleh Anvar, Alexandra M. Stevens, Ryan Kolb, Chen Zhao, Zhijian Qian, Jatinder K. Lamba, Guangrong Zheng, Weizhou Zhang
bioRxiv (Cold Spring Harbor Laboratory)
초록
IKKβ and NR4A1 are clinically relevant mediators of AML pathogenesis.A novel celastrol-based PROTAC can effectively degrade both IKKβ and NR4A1 to disrupt AML pathogenesis.
키워드
Dual (grammatical number)Myeloid leukemiaBlockadeDrugCancer